BioTX Automation, Inc.

Based in Warren, NJ, Snova is a privately held bio-tech company. Currently, there are 100 employees at Snova worldwide. The company focuses on research and development of in-vitro molecular diagnostic kits, molecular biology enzymes, DNA purification kit and related bio-engineering technologies and equipment. In addition to research and development, Snova also do manufacturing, marketing and sales of biological reagents globally.

Bio-synthesis is a biology contract manufacturer of high quality nucleic acids, peptides and other molecular biology products for the research, diagnostic and therapeutic industries. Bio-Synthesis operates an ISO 9001 certified facility and is compliant with 21 CFR 210/211 and 21 CFR 820. Our solutions help advance drug discovery and bio-medical research. Founded in 1984, Bio-Synthesis is a privately held firm based in Lewisville, Texas.

Custom Peptide Specialists
Bio-Synthesis has been a provider of Peptide Synthesis services to the life science research community since 1984. We offer a complete range of premium quality peptide products ranging from bulk API polypeptides to high throughput library peptides and peptide array preparation. We also provide a large number of peptide modifications as well as peptide synthesis for diagnostic and therapeutic applications. Bio-Synthesis specializes in both, liquid phase and solid phase fmoc peptide synthesis chemistry. We have a long standing record in preparing biologically active polypeptides including long, complex and hydrophobic peptides synthesized to your specifications.

Custom Oligonucleotide Specialists
As a pioneer in oligonucleotide synthesis, Bio-Synthesis has been pursuing the development of new oligonucleotide-based techniques that can produce compounds with superior binding affinity and chemical/biological stability. As such, Bio-Synthesis has introduced a third generation of nucleic acid analogs, Bridged Nucleic Acid (BNA). These are RNA analogues which can be synthesized and spiked with DNA or RNA in order to modify the formation of nucleic acid helices.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market. Biocartis employs over 500 people and is headquartered in Mechelen, Belgium. Further information? Visit www.biocartis.com

Founded in 2002, CELPROGEN is a biotechnology company, with over 5000 products in the market, focused on developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes & neurology. All of Celprogen’s biological products, including stem cells, cancer stem cells, iPC’s & media with specific ECM’s, are manufactured and produced in the United States of America.

CELPROGEN provides novel molecular diagnostics and therapeutic product development solutions for Biotechnology, Pharmaceutical, In-vitro diagnostics and academic partnership for drug discovery.

It has 3 divisions:

• Therapeutic Division: Focused on Drug Discovery efforts to develop Pharmaceutical agents and Drugs in the following categories: Cardiovascular, Diabetes, Neurological, Oncology,Renal and Metabolic disorders.
• Life Science Division: Provides research tools & solutions for assays, enzymes, antibodies, antigens, stem cells, Tissue culture expansion and differentiation media, primary and established cell cultures, tumor markers, cardiac markers, proteomic and genomic reagents and assay systems for life science academic and pharmaceutical communities.
• Device Division: Provides novel ELISA based assay, protein array, DNA array and cellular based assay systems that are cost effective for Research and In-vitro diagnostics Industries.

NOW PART OF TAKARA BIO USA, INC. -- Please visit the Takara Bio USA, Inc. company page for the latest updates: https://www.linkedin.com/company-beta/17509/

WaferGen automation systems include innovative genomic technology solutions for single-cell analysis and clinical research.

The ICELL8® Single-Cell System is a revolutionary platform which can isolate thousands of single cells and enables selection and processing of specific cells for various analysis methods, including next generation sequencing. The system has demonstrated unbiased isolation of up to 1,800 single cells 5–100 µm in size on a single chip, including cells from solid tumors and brain tissues, pulmonary airway cells, and multiple cell lines.

The SmartChip™ platform can be used for profiling and validating molecular biomarkers, and can perform massively parallel singleplex PCR for one-step NGS library preparation in clinical applications.

The Apollo™ 324 system can be used to process DNA and RNA obtained from clinical samples into NGS-ready libraries.

These technologies offer a powerful set of tools for biological analysis at the molecular and single-cell levels in the life sciences, pharmaceutical, and clinical laboratory industries.